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Purpose: The objective of this study is to examine heterogeneity among
clinical/symptomatic and radiographic osteoarthritis (COA/ROA) pheno-
types. The need for standardization of OA phenotypes in epidemiological
studies is addressed.
Methods: We collected descriptions of all OA phenotypes within the 28
studies involved in the TREAT-OA consortium. There are 18 cohort studies,
9 case-control studies and 1 randomized-controlled trial.
To discover if differences in OA deﬁnitions result in different association
results, we created all hip OA deﬁnitions used by studies of the consortium
in the Rotterdam Study-I. Association analyses were performed to study
the relationship between different OA deﬁnitions of the hip and age, gender
and (BMI) using one-way ANOVA.
After consensus was reached for the deﬁnition of knee and hip ROA, each
study standardized its ROA phenotype deﬁnitions and the prevalence of
ROA of the knee and hip was compared before and after standardization
for 6 cohort studies.
Results: A total of 54% (15/28) of studies deﬁned OA according to radio-
graphic features, while 46% (13/28) used a clinical or clinical + radiographic
OA deﬁnition. All studies with COA (n=11) used a different deﬁnition and/or
assessment of OA status for COA of the knee (n=10), hip (n=8) and hand
(n=2). For knee, hip and hand ROA, 5, 4 and 6 different ROA deﬁnitions
were used respectively.
When hip OA was deﬁned as one deﬁnite osteophyte, subjects with hip OA
were signiﬁcantly more frequent men compared to controls (P=2×10E10),
whilst total hip replacement cases were more frequent women compared
to controls (P=1×10E4). If ROA deﬁnitions are compared, we observed
that hip ROA deﬁned as deﬁnite JSN and one deﬁnite osteophyte was not
associated with BMI (p=0.94), whilst hip OA cases deﬁned as only one
deﬁnite osteophyte were associated with a slightly lower BMI (p=0.049).
After standardization, the prevalence of hip- and knee ROA was similar
in 6 cohort studies. Standardization of clinical OA phenotypes, although
desirable, was not possible due to the case-control study design of the
studies.
Conclusions: 1. Phenotype deﬁnitions do inﬂuence the outcomes in as-
sociation studies and therefore ROA phenotypes within the TREAT-OA
consortium were standardized to reduce heterogeneity. A standardized
ROA phenotype deﬁnition will improve the power in the anticipated
genetics studies.
2. Additional research is needed to reach a consensus for deﬁnitions of
clinical/symptomatic OA. We suggest that more thought should be given
to the establishment of clear guidelines for future research using clini-
cal/symptomatic OA cohorts, as this would have implications not just for
genetic studies, but also for the assessment of biomarkers, imaging and
interventional studies.
3. In the future, more precise OA phenotypes and stratiﬁcation according
to phenotypes should be mandatory for inclusion in large meta-analyses.
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Purpose: To identify the costs associated with knee OA in an elderly
Swedish population, from a societal perspective.
Methods: A questionnaire about knee pain was sent to 10,000 partici-
pants (age range 56-84 years) from the population-based Malmö Diet and
Cancer cohort (responders: 7,736). A random sample of 1,300 subjects
with chronic knee pain (duration of at least one month in the last year)
and a control group (650 subjects) were invited to a clinical examination
including x-ray of both knees (998 + 487 subjects underwent examination
and x-ray). Subjects who fulﬁlled ACR criteria and/or had radiographic knee
OA (ROA) were considered to have knee OA. The direct costs estimated
were hospitalizations, visits to nurse/GP, physiotherapist or knee specialist,
call to nurse/GP, and drugs, due to knee pain. The indirect costs estimated
were sick-leave and pre-retirement, due to knee pain.
Results: Approximately 20% (1,605/7,736) of the subjects had chronic
knee pain. Of those that participated in the examination and x-ray, 50%
(502/998) had knee OA. Among subjects with knee OA and chronic knee
pain; 39% had direct costs and 4% indirect costs, as compared to 20% and
1.6%, respectively, among subjects with chronic knee pain, but no knee OA,
and 3% and 0%, respectively, among control subjects. The mean total yearly
cost (direct + indirect) per subject with knee OA and chronic knee pain
was €1,715. The major contributor (71%) was indirect costs (sick-leave and
pre-retirement). The total costs for the subjects who fulﬁlled ACR criteria
were approximately 70% higher than for those who had ROA (€2,060 vs.
€1,189). Both females and males of age <65 years or age 65≥ with knee
OA and chronic knee pain had signiﬁcantly higher total costs than subjects
of the same sex and age group with chronic knee pain, but no knee OA.
Females of age <65 years with knee OA, or with chronic knee pain but no
knee OA, had signiﬁcantly higher total costs than females of age 65≥ in the
same diagnostic group. A similar signiﬁcant age dependence was not seen
in males.
Conclusions: A large proportion (50%) of the subjects with chronic knee
pain had knee OA. Total costs were markedly dependent on diagnostic
group, age and sex. The major contributor (71%) was indirect costs driven
by 4% of the subjects. If the prevalence rates and costs from this study
could be extrapolated to the general 56-84 year old population in Sweden,
this would correspond to approximately 260 000 Swedish individuals with
chronic knee pain and knee OA and a total annual cost of €560 millions.
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Purpose: To evaluate the inﬂuence of WOMAC total score on direct and in-
direct costs associated with chronic knee pain, with or without a diagnosis
for osteoarthritis, in an elderly Swedish population.
Methods: A random sample of subjects with self-assessed chronic knee
pain (duration for at least one month in the last year) was drawn from the
population-based Malmö Diet and Cancer cohort. After clinical examination,
including X-ray, subjects were divided into two diagnostic groups:
“OA” (n=502): Subjects with chronic knee pain fulﬁlling ACR criteria and/or
having a radiographic diagnosis of osteoarthritis.
“Pain” (n=496): Subjects with chronic knee pain but no diagnosis of
osteoarthritis.
For each subject, sex, age, body mass index (BMI) and WOMAC total score
were assessed, and the total yearly costs per patient estimated. Total
costs included direct costs (hospitalizations, visits to GP/knee specialist/
nurse/physiotherapist and medications due to knee pain) and indirect costs
(sick-leave and pre-retirement). The quantitative inﬂuence on total costs
from the WOMAC total score, and from the demographic variables, was
